Related Experiment Video
Updated: Mar 24, 2026

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Autologous tumor immunizing devascularization in cancer therapy
Vladimir Kalina1, David J Kopsky2
1Nestlé Research Center Lausanne, Switzerland.
Abstract:
Tumor vaccination depending on specific antigens, autologous tumor vaccination involving wide range of antigens, immunomodulating cytokines and bacterial agents have been studied extensively with the purpose of stimulating the antitumor immune response. Unfortunately these therapies showed disappointing results mainly due to undesirable mechanisms tending to dampen the antitumor immune response. We will discuss a novel approach of autologous tumor immunization using a surgical technique: autologous tumor immunizing devascularization (ATID). This approach involves complete surgical devascularization of a tumor which is then left isolated in situ in the body. The stressing pathophysiological condition of the completely isolated tumor provokes a generalized immune response which, as shown from clinical cases, leads to the elimination of the devascularized tumor and distant metastases without causing sepsis. Until now no clinical study was properly executed. The possible significance of this method which resides in its curative potential has thus escaped attention in the field of cancer therapy. This article will hypothesize optimal physiological criteria and necessary clinical conditions for ATID to be performed effectively. The main criteria are (1) complete isolation of the tumor from the vascular system, (2) sufficient devascularized tumor load to trigger a sustained generalized immune response to cancer antigens until elimination of all cancer loci, (3) tumor cell killing rate corresponding to the elicited immune response is higher than the tumor cell growth rate, and (4) patients with an uncompromised immune system. Future studies have to be performed under the indicated conditions in order to confirm the efficacy and safety of ATID as a novel approach in the treatment of cancer.
Insights
Autologous tumor immunization using devascularization (ATID) is a novel surgical approach. This method isolates tumors to provoke an immune response, potentially eliminating tumors and metastases without sepsis.
Area of Science:
- Oncology
- Immunology
- Surgical Oncology
Background:
- Previous cancer immunotherapies like tumor vaccination have shown limited success due to mechanisms that suppress antitumor immunity.
- Autologous tumor vaccination, cytokine therapy, and bacterial agents have been explored but yielded disappointing results.
Purpose of the Study:
- To introduce and discuss a novel surgical technique for autologous tumor immunization called autologous tumor immunizing devascularization (ATID).
- To hypothesize optimal physiological and clinical conditions for effective ATID implementation.
- To highlight the potential curative significance of ATID in cancer therapy.
Main Methods:
- ATID involves complete surgical devascularization of a tumor, leaving it isolated in situ.
- The pathophysiological stress on the isolated tumor aims to induce a generalized immune response.
- The study hypothesizes criteria for effective ATID, including complete vascular isolation, sufficient tumor load, a tumor cell killing rate exceeding growth rate, and patients with intact immune systems.
Main Results:
- Clinical cases suggest ATID can lead to the elimination of devascularized tumors and distant metastases.
- The process has reportedly occurred without causing sepsis.
- No formal clinical studies have been executed to validate these observations.
Conclusions:
- ATID presents a novel approach with potential curative capabilities in cancer treatment.
- Further clinical studies under rigorously defined conditions are necessary to confirm ATID's efficacy and safety.
- Establishing optimal physiological criteria and clinical conditions is crucial for successful ATID application.

